Although these products were not genetically modified to resist infection, it is unlikely that direct infection of the low percentage of CD4+ CE-XTC in each infused product contributed to the low frequency of infused cells in the blood or lack of protection against mucosal SHIV challenge. This evidence concerns the gene CD4 and infection.